Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  MacIsaac, Kenzie D ^a   Baumgartner, Richard ^a   Kang, Jia ^a   Loboda, Andrey ^a   Peterfy, Charles ^b   DiCarlo, Julie ^b   Riek, Jonathan ^c   Beals, Chan ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Spire Sciences Inc   (United States)

^c VirtualScopics LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GADOLINIUM; INFLIXIMAB; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ACAT1 GENE; ADULT; AFF3 GENE; ANKRD55 GENE; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CELL ACTIVATION; CELL MOTILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORO1C GENE; CXCR4 GENE; DAS28; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FAM167A GENE; FCGR3B GENE; FCRL1 GENE; FCRLA GENE; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IKZF3 GENE; IL7R GENE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MONOCYTE; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; PLATELET FACTOR 4 GENE; RAMRIS METHOD; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVITIS; SYNOVIUM; THROMBOCYTE; TPD52 GENE; VIMENTIN GENE; VISUAL ANALOG SCALE; WRIST; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MIDDLE AGED; MOLECULAR GENETICS; MULTICENTER STUDY; PATHOLOGY; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLIXIMAB; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SEQUENCE ANALYSIS, RNA; TREATMENT OUTCOME; WRIST;

EID: 84917734196     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113937     Document Type: Article

References (44)

1. Hyrich KL, Watson KD, Silman AJ, Symmons DPM (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45: 1558-1565.
2. Bienkowska JR, Dalgin GS, Batliwalla F, Allaire N, Roubenoff R, et al. (2009) Convergent Random Forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response. Genomics 94: 423-432.
3. Julià A, Erra A, Palacio C, Tomas C, Sans X, et al. (2009) An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One 4.
4. Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, et al. (2008) Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 10.
5. Lequerre T, Gauthier-Jauneau A-C, Bansard C, Derambure C, Hiron M, et al. (2006) Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 8.
6. Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, et al. (2008) Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford) 47: 780-788.
7. Stuhlmuller B, Haupl T, Hernandez MM, Grutzkau A, Kuban RJ, et al. (2010) CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther 87: 311-321.
8. Tanino M, Matoba R, Nakamura S, Kameda H, Amano K, et al. (2009) Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. Biochem Biophys Res Commun 387: 261-265.
9. van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, et al. (2010) Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 12.
10. Toonen EJM, Gilissen C, Franke B, Kievit W, Eijsbouts AM, et al. (2012) Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. PLoS One 7.
11. Strand V, Cohen S, Crawford B, Smolen JS, Scott DL (2004) Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford) 43: 640-647.
12. Ostergaard M, Stoltenberg M, Lovgreen-Nielsen P, Volck B, Sonne-Holm S, et al. (1998) Quantification of synovistis by MRI: correlation between dynamic and static gadolinium-enhanced magnetic resonance imaging and microscopic and macroscopic signs of synovial inflammation. Magn Reson Imaging 16: 743-754.
13. Workie DW, Dardzinski BJ (2005) Quantifying dynamic contrast-enhanced MRI of the knee in children with juvenile rheumatoid arthritis using an arterial input function (AIF) extracted from popliteal artery enhancement, and the effect of the choice of the AIF on the kinetic parameters. Magn Reson Med 54: 560-568.
14. Hodgson RJ, O'Connor P, Moots R (2008) MRI of rheumatoid arthritis image quantitation for the assessment of disease activity, progression and response to therapy. Rheumatology (Oxford) 47: 13-21.
15. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48.
16. McQueen F, Lassere M, Edmonds J, Conaghan P, Peterfy C, et al. (2003) OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR Imaging Module. J Rheumatol 30: 1387-1392.
17. Liang KY ZS (2000) Longitudinal data analysis of continuous and discrete responses for pre-post designs. Indian Journal of Statistics 62: 134-148.
18. Fransen J, van Riel PLCM (2005) The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23: 93-99.
19. Okada Y, Wu D, Trynka G, Raj T, Terao C, et al. (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506: 376-381.
20. Van Steendam K, Tilleman K, Deforce D (2011) The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 50: 830-837.
21. Parker A, Izmailova ES, Narang J, Badola S, Le T, et al. (2007) Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol 34: 1817-1822.
22. Villalvilla A, Gomez R, Roman-Blas JA, Largo R, Herrero-Beaumont G (2014) SDF-1 signaling: a promising target in rheumatic diseases. Expert Opin Ther Targets 18: 1077-1087.
23. Trocme C, Marotte H, Baillet A, Pallot-Prades B, Garin J, et al. (2009) Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 68: 1328-1333.
24. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, et al. (2008) A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29: 150-164.
25. Prajapati R, Plant D, Barton A (2011) Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 12: 1571-1585.
26. Greenwood MC, Rathi J, Hakim AJ, Scott DL, Doyle DV (2007) Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-alpha inhibitors in adults with rheumatoid arthritis. Rheumatology (Oxford) 46: 1165-1167.
27. American College of Rheumatology Rheumatoid Arthritis Clinical Trial Investigators Ad Hoc Task F (2011) American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010. Arthritis Rheum 63: 2151-2156.
28. Peterfy C, Ostergaard M, Conaghan PG (2013) MRI comes of age in RA clinical trials. Ann Rheum Dis 72: 794-796.
29. American College of Rheumatology Rheumatoid Arthritis Clinical Trials Task Force Imaging G, Outcome Measures in Rheumatology Magnetic Resonance Imaging Inflammatory Arthritis Working G (2013) Review: the utility of magnetic resonance imaging for assessing structural damage in randomized controlled trials in rheumatoid arthritis. Arthritis Rheum 65: 2513-2523.
30. Axelsen MB, Poggenborg RP, Stoltenberg M, Kubassova O, Boesen M, et al. (2013) Reliability and responsiveness of dynamic contrast-enhanced magnetic resonance imaging in rheumatoid arthritis. Scand J Rheumatol 42: 115-122.
31. Hodgson R, Grainger A, O'Connor P, Barnes T, Connolly S, et al. (2008) Dynamic contrast enhanced MRI of bone marrow oedema in rheumatoid arthritis. Ann Rheum Dis 67: 270-272.
32. Orguc S, Tikiz C, Aslanalp Z, Erbay PD (2013) Comparison of OMERACT-RAMRIS scores and computer-aided dynamic magnetic resonance imaging findings of hand and wrist as a measure of activity in rheumatoid arthritis. Rheumatol Int 33: 1837-1844.
33. Coulthard LR, Geiler J, Mathews RJ, Church LD, Dickie LJ, et al. (2012) Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients. Clin Exp Immunol 170: 36-46.
34. Oduro KA, Liu F, Tan Q, Kim C-K, Lubman O, et al. (2012) Myeloid skewing in murine autoimmune arthritis occurs in hematopoietic stem and primitive progenitor cells. Blood 120: 2203-2213.
35. Leizer T, Cebon J, Layton JE, Hamilton JA (1990) Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor. Blood 76: 1989-1996.
36. Kaushansky K, Broudy VC, Harlan JM, Adamson JW (1988) Tumor necrosis factor-alpha and tumor necrosis factor-beta (lymphotoxin) stimulate the production of granulocyte-macrophage colonystimulating factor, macrophage colony-stimulating factor, and IL-1 in vivo. J Immunol 141: 3410-3415.
37. Boilard E, Blanco P, Nigrovic PA (2012) Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 8: 534-542.
38. Pignatelli P, De Biase L, Lenti L, Tocci G, Brunelli A, et al. (2005) Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. Blood 106: 1992-1994.
39. Dan K, Gomi S, Inokuchi K, Ogata K, Yamada T, et al. (1995) Effects of interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis. Acta Haematol 93: 67-72.
40. Meany HJ, Seibel NL, Sun J, Finklestein JZ, Sato J, et al. (2008) Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor. J Immunother 31: 679-683.
41. Piguet PF, Vesin C, Da Kan C (2002) Activation of platelet caspases by TNF and its consequences for kinetics. Cytokine 18: 222-230.
42. Tacchini-Cottier F, Vesin C, Redard M, Buurman W, Piguet PF (1998) Role of TNFR1 and TNFR2 in TNF-induced platelet consumption in mice. J Immunol 160: 6182-6186.
43. Ueda Y, Yang K, Foster SJ, Kondo M, Kelsoe G (2004) Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression. J Exp Med 199: 47-58.
44. Kekow J, Mueller-Ladner U, Schulze-Koops H (2012) Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFa blocker failure. Biologics 6: 191-199.